{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Cancer%2C+Metastatic&page=13", "query": { "condition": "Gastric Cancer, Metastatic", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 514, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Cancer%2C+Metastatic&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Cancer%2C+Metastatic&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T12:14:51.456Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02314117", "title": "A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 645, "start_date": "2015-01-20", "completion_date": "2020-08-14", "has_results": true, "last_update_posted_date": "2021-08-26", "last_synced_at": "2026-10-15T12:14:51.456Z", "location_count": 25, "location_summary": "Fayetteville, Arkansas • Bakersfield, California • Fullerton, California + 19 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02314117" }, { "nct_id": "NCT00517829", "title": "Docetaxel+Oxali+/-Cetux Met Gastric/GEJ", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer Adenocarcinoma Metastatic" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2007-07", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2016-11-28", "last_synced_at": "2026-10-15T12:14:51.456Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Port Richey", "state": "Florida" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00517829" }, { "nct_id": "NCT04727151", "title": "TAC T-cells for the Treatment of HER2-positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2 Positive Gastric Cancer", "Metastatic HER2 Positive Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "TAC01-HER2", "type": "BIOLOGICAL" }, { "name": "TAC01-HER2 plus pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Triumvira Immunologics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2021-04-19", "completion_date": "2024-03-25", "has_results": true, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-10-15T12:14:51.456Z", "location_count": 9, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Newark, New Jersey + 5 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Newark", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04727151" }, { "nct_id": "NCT01697072", "title": "First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Rilotumumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 609, "start_date": "2012-10", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2016-02-09", "last_synced_at": "2026-10-15T12:14:51.456Z", "location_count": 16, "location_summary": "Tucson, Arizona • Aurora, Colorado • Pueblo, Colorado + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Pueblo", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01697072" }, { "nct_id": "NCT05185947", "title": "Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gynecologic Cancer", "Gynecologic Neoplasms", "Peritoneal Carcinomatosis", "Peritoneal Neoplasms", "Ovarian Cancer", "Ovarian Neoplasms", "Colorectal Cancer", "Colorectal Neoplasms", "Appendiceal Cancer", "Appendiceal Neoplasms", "Cholangiocarcinoma", "Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "CT Scan CAP", "type": "DIAGNOSTIC_TEST" }, { "name": "Laparoscopy", "type": "PROCEDURE" }, { "name": "Peritoneal biopsies + ascites washings", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2022-10-13", "completion_date": "2025-01-27", "has_results": true, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-15T12:14:51.456Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05185947" }, { "nct_id": "NCT03993873", "title": "Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumors", "MET Gene Alterations" ], "interventions": [ { "name": "elzovantinib (TPX-0022)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Turning Point Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2019-09-05", "completion_date": "2027-03-03", "has_results": false, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-10-15T12:14:51.456Z", "location_count": 12, "location_summary": "La Jolla, California • Orange, California • Denver, Colorado + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03993873" }, { "nct_id": "NCT02714374", "title": "GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Organ Cancers" ], "interventions": [ { "name": "GL-ONC1", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Andrew Lowy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2016-03-25", "completion_date": "2019-08-06", "has_results": false, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-10-15T12:14:51.456Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02714374" }, { "nct_id": "NCT05107674", "title": "A Study of NX-1607 in Adults With Advanced Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer, Epithelial", "Gastric Cancer", "GastroEsophageal Junction (GEJ) Cancer", "Head and Neck Squamous Cell Carcinoma", "Metastatic or Unresectable Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Metastatic Castration-resistant Prostate Cancer (mCRPC)", "Malignant Pleural Mesothelioma (MPM)", "Triple Negative Breast Cancer (TNBC)", "Metastatic Urothelial Carcinoma", "Cervical Cancer", "Diffuse Large B Cell Lymphoma (DLBCL)", "Richter Transformation", "Microsatellite Stable Colorectal Carcinoma" ], "interventions": [ { "name": "NX-1607", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nurix Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 345, "start_date": "2021-09-29", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-10-15T12:14:51.456Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05107674" }, { "nct_id": "NCT04683939", "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma", "Pancreatic Cancer", "Biliary Tract Cancer", "Cholangiocarcinoma", "Metastatic Cancer" ], "interventions": [ { "name": "BNT141", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2022-01-18", "completion_date": "2023-07-24", "has_results": true, "last_update_posted_date": "2024-10-02", "last_synced_at": "2026-10-15T12:14:51.456Z", "location_count": 4, "location_summary": "Duarte, California • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04683939" }, { "nct_id": "NCT00620607", "title": "huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stomach Neoplasms", "Metastatic or Locally Advanced Gastric Cancer", "Metastatic or Local Advanced GE Junction Cancer" ], "interventions": [ { "name": "huC242-DM4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2007-05", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2015-08-26", "last_synced_at": "2026-10-15T12:14:51.456Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Nashville, Tennessee • Houston, Texas + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00620607" } ] }